Compare GSK plc (GSK) vs J B Hunt Transport Services Inc (JBHT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs J B Hunt Transport Services Inc — how do they compare? GSK plc trades at $46.5 (market cap $91.88B), while J B Hunt Transport Services Inc trades at $229.26 (market cap $21.45B). The key difference: GSK plc is far larger — about 4.3× J B Hunt Transport Services Inc's market cap, and GSK plc pays the higher dividend (3.9%). Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and J B Hunt Transport Services Inc for 46 Days on average.
| GSK | JBHT | |
|---|---|---|
Market Cap | $91.88B | $21.45B |
Volume | 7,730,529 | 1,028,680 |
Sector | Health | Industrials |
52-Week High | $61.18 | $298.41 |
52-Week Low | $43.24 | $137.09 |
Typical Hold Time | 93 Days | 46 Days |
Enterprise Value | $111.88B | $22.59B |
Dividend Yield | 3.9% | 0.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.54, down 1.02% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.36 exceeding the $1.27 estimate. Fundamentals show robust profitability with a 72.73% gross margin and 14.52% net margin, while valuation metrics like a P/E of 14.89 appear reasonable. Recent news highlights pipeline advancements, including a $750 million cancer therapy deal and strategic focus on oncology and cost savings.
The outlook is mixed; analyst consensus leans Hold (55.18%) with a minority Buy rating (31.03%), reflecting caution amid an approaching HIV patent cliff. Near-term support is at $45, with resistance at $47. Revenue growth to $33.2B in 2026 and a dividend of $0.45 per share offer stability, but execution risks and competitive pressures remain key watchpoints for investors.
JBHT trades at $228.42, up 2.6% with strong earnings beats in recent quarters. Technical indicators show bearish momentum with support at $225 and resistance at $230. The company maintains solid fundamentals with $12B revenue, 5.31% net margin, and 18.45% ROE, though valuation metrics appear elevated with P/E of 32.5. Recent news highlights ongoing securities investigations and Q3 earnings anticipation.
Outlook remains cautiously optimistic with analyst consensus price target of $289.40 (27% upside) and 59% buy ratings. Key risks include legal investigations, cost pressures from diesel prices, and competitive trucking industry. Earnings growth and freight demand provide catalysts, but legal overhang warrants monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About J B Hunt Transport Services Inc
J.B. Hunt Transport Services ranks among the top surface transportation companies in North America by revenue. Its primary operating segments are intermodal delivery, which uses the Class I rail carriers for the underlying line-haul movement of its owned containers (45% of sales in 2021).
Read more on JBHT →
